STAT+: Argenx sees unusual setback with failure of late-stage study of drug for autoimmune disease
Phase 3negativeVyvgartNegative
AI Analysis
Summary
Argenx's blockbuster drug Vyvgart failed to outperform placebo in a Phase 3 trial for Sjögren's disease, representing a significant late-stage development setback for the company.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Failed to outperform placebo in Phase 3 trial for Sjögren's disease
Importance:8/10
Sentiment:
-0.95
Phase 3 failureautoimmune diseaseclinical trial setbackSjögren's disease
Related Companies
Read the original article
Published by STAT News on October 8, 2026 2:02 PM